Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
EyePoint Pharmaceuticals, Inc is a biotechnology business based in the US. EyePoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. EyePoint Pharmaceuticals employs 84 staff and has a trailing 12-month revenue of around USD$35.9 million.
|Latest market close||USD$4.49|
|52-week range||USD$3.511 - USD$21|
|50-day moving average||USD$4.585|
|200-day moving average||USD$5.7864|
|Wall St. target price||USD$22.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.721|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-59.00%|
|1 month (2020-12-24)||-10.02%|
|3 months (2020-10-22)||858.99%|
|6 months (2020-07-22)||497.95%|
|1 year (2020-01-22)||178.88%|
|2 years (2019-01-22)||97.80%|
|3 years (2018-01-22)||308.18%|
|5 years (2016-01-22)||25.77%|
|Revenue TTM||USD$35.9 million|
|Gross profit TTM||USD$2.3 million|
|Return on assets TTM||-26.42%|
|Return on equity TTM||-342.81%|
|Market capitalisation||USD$71.5 million|
TTM: trailing 12 months
There are currently 348,813 EyePoint Pharmaceuticals shares held short by investors – that's known as EyePoint Pharmaceuticals's "short interest". This figure is 66.7% up from 209,255 last month.
There are a few different ways that this level of interest in shorting EyePoint Pharmaceuticals shares can be evaluated.
EyePoint Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyePoint Pharmaceuticals shares currently shorted divided by the average quantity of EyePoint Pharmaceuticals shares traded daily (recently around 198189.20454545). EyePoint Pharmaceuticals's SIR currently stands at 1.76. In other words for every 100,000 EyePoint Pharmaceuticals shares traded daily on the market, roughly 1760 shares are currently held short.
However EyePoint Pharmaceuticals's short interest can also be evaluated against the total number of EyePoint Pharmaceuticals shares, or, against the total number of tradable EyePoint Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyePoint Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 EyePoint Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0322% of the tradable shares (for every 100,000 tradable EyePoint Pharmaceuticals shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against EyePoint Pharmaceuticals.
Find out more about how you can short EyePoint Pharmaceuticals stock.
We're not expecting EyePoint Pharmaceuticals to pay a dividend over the next 12 months.
EyePoint Pharmaceuticals's shares were split on a 1:10 basis on 9 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyePoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for EyePoint Pharmaceuticals shares which in turn could have impacted EyePoint Pharmaceuticals's share price.
Over the last 12 months, EyePoint Pharmaceuticals's shares have ranged in value from as little as $3.511 up to $21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyePoint Pharmaceuticals's is 1.5144. This would suggest that EyePoint Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.